South Korea Neurodegenerative Disease Market Research Report By Disease Type (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Huntington's Disease), By Diagnosis Method (Neurological Examination, Imaging Techniques, Cerebrospinal Fluid Analysis, Electrophysiological Tests), By Treatment Type (Medication, Therapy, Rehabilitation, Surgical Interventions) and By Route of Administration (Oral, Injectable, Intravenous, Transdermal)-Forecast to 2035

South Korea Neurodegenerative Disease Market Overview

As per MRFR analysis, the South Korea Neurodegenerative Disease Market Size was estimated at 442 (USD Million) in 2023. The South Korea Neurodegenerative Disease Market Industry is expected to grow from 466.6(USD Million) in 2024 to 1,200 (USD Million) by 2035. The South Korea Neurodegenerative Disease Market CAGR (growth rate) is expected to be around 8.967% during the forecast period (2025 - 2035).

Key South Korea Neurodegenerative Disease Market Trends Highlighted

The South Korea Neurodegenerative Disease Market is witnessing significant market trends driven by an aging population and increasing prevalence of diseases such as Alzheimer's and Parkinson's. The government of South Korea has initiated various healthcare programs aimed at early diagnosis and innovative treatment methods for neurodegenerative diseases. This effort has accelerated research and development in the biotech sector, as there is a strong focus on creating new therapies and incorporating advanced technologies like artificial intelligence into treatment protocols. Opportunities exist for companies to explore cutting-edge solutions such as gene therapy and stem cell treatments, motivating them to expand their R&D capabilities.In recent times, there has been a marked increase in collaborative efforts between South Korean universities and research institutions, fostering innovation within the neurodegenerative disease sector. These collaborations are crucial as they optimize resource sharing and accelerate the drug development process. Furthermore, rising public awareness about mental health and neurodegenerative disease is prompting greater investment from both public and private sectors into specialized healthcare facilities and support services. This cultural shift is opening up avenues for startups focusing on digital health platforms that support patients and caregivers.The South Korean government is also supporting initiatives to improve the quality of life for elderly patients suffering from neurodegenerative conditions. Programs that encourage home care services and telehealth solutions are becoming increasingly popular, as they allow for more accessible and personalized care. Overall, the landscape of the South Korea Neurodegenerative Disease Market is evolving rapidly, presenting numerous opportunities for innovation and effective treatment strategies to better address the challenges posed by these debilitating diseases.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

South Korea Neurodegenerative Disease Market Drivers

Increasing Aging Population

South Korea's elderly population is rapidly increasing, which is driving the expansion of the South Korea Neurodegenerative Disease Market Industry. According to Alzheimer's Disease International, the number of persons aged 65 and older in South Korea is predicted to reach 14.8 million by 2050, up from around 8.9 million in 2020. This demographic change causes an increase in the prevalence of neurological disorders, including Alzheimer's and Parkinson's. With official data from the Korean Statistical Information Service indicating that the elderly population will reach 40% by 2060, demand for neurodegenerative treatments and supportive services is expected to rise, driving market growth and prompting investments from key stakeholders such as the Korean Institute of Health and Social Affairs in research initiatives and elderly care services.

Advancements in Research and Development

The South Korea Neurodegenerative Disease Market Industry is witnessing significant advancements in Research and Development (R&D) activities, enhancing treatment modalities for neurodegenerative diseases. The South Korean government has increased funding for innovative healthcare initiatives, with the Ministry of Health and Welfare reporting an allocation of 600 billion KRW for R&D in the healthcare sector in 2021. As a result, many biotechnology companies, such as Samsung Biologics and Celltrion, are actively engaging in the development of new therapies and medicines targeting neurodegenerative diseases.This trend is expected to fuel the market's growth, given that emerging treatments can significantly improve patient outcomes and address critical unmet needs in the community.

Growing Awareness and Diagnosis

There is an increasing awareness and improved diagnostic methods for neurodegenerative diseases in South Korea, which plays a pivotal role in the expansion of the South Korea Neurodegenerative Disease Market Industry. Campaigns by the Korean Alzheimer’s Association have significantly raised public awareness, leading to better recognition of symptoms and earlier diagnosis. Moreover, a report from the Korea Institute for Health and Social Affairs highlights that the number of diagnosed Alzheimer's cases has risen by 15% over the past five years.This spike in awareness is critical, as earlier intervention can lead to better management of conditions, prompting healthcare providers to invest more in diagnostic tools and therapeutic solutions to meet the rising demand.

South Korea Neurodegenerative Disease Market Segment Insights

Neurodegenerative Disease Market Disease Type Insights

The South Korea Neurodegenerative Disease Market, within the context of Disease Type, encompasses various critical ailments, each with unique characteristics and demands. Among these, Alzheimer’s Disease stands out as a significant contributor to market growth, driven by an aging population and increasing awareness surrounding cognitive health. The prevalence of Alzheimer’s in South Korea has led to sophisticated Healthcare strategies aimed at early diagnosis and treatment, prompting innovations in Research and Development throughout the industry. Similarly, Parkinson’s Disease represents another vital area within this segment, characterized by its profound impact on motor functions, calling for robust therapeutic approaches. The South Korean government has recently emphasized the importance of personalized medicine to address the specific needs of patients suffering from this debilitating condition.Multiple Sclerosis, while less prevalent than Alzheimer’s and Parkinson’s, still commands attention within healthcare frameworks in South Korea due to its challenging nature and the importance of holistic patient management. The increasing number of cases is prompting collaborations among academic institutions and biotech firms to develop targeted therapies. Furthermore, Amyotrophic Lateral Sclerosis stands as one of the most critical focal points in neurodegenerative research, with significant implications for healthcare systems, as it requires advanced caregiving solutions. The community response has led to support networks and awareness campaigns, significantly enhancing public understanding and engagement with this severe illness. Huntington's Disease, though rarer, contributes to the landscape by highlighting the need for advances in genetic research and therapy development. Moreover, the South Korea Neurodegenerative Disease Market segmentation shows that caregivers, families, and patients emphasize quality of life and access to groundbreaking treatments, influencing the trajectory of both policy and resource allocation. This highlights the inherent challenges and opportunities within the market, driven by the need to improve diagnostic methods and therapeutic interventions across the various disease types. Collectively, these disorders represent crucial areas of focus for the South Korean healthcare system, tailored to manage the complexities associated with neurodegenerative diseases effectively. As the nation develops its policies and resources, the continuous evolution of treatment strategies remains a key component of addressing the implications of these diseases on society.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Neurodegenerative Disease Market Diagnosis Method Insights

The Diagnosis Method segment within the South Korea Neurodegenerative Disease Market encompasses critical techniques that play an essential role in the accurate identification of various neurodegenerative conditions. Neurological Examination offers vital preliminary assessments, enabling healthcare professionals to evaluate patients efficiently and formulate further diagnostic pathways. Imaging Techniques, such as MRI and CT scans, provide sophisticated visualization of brain structures, aiding in the detection of encephalopathies and other abnormalities. Cerebrospinal Fluid Analysis is crucial in diagnosing conditions like Alzheimer's and multiple sclerosis, as it allows for the assessment of biomarkers indicative of these diseases. Meanwhile, Electrophysiological Tests, including EEGs, are significant for diagnosing movement disorders and assessing neuronal activity. Overall, these methods collectively enhance diagnosis accuracy, ultimately leading to improved treatment outcomes. The integration of advanced diagnostic technologies is projected to drive innovation in the field, addressing the growing demand for effective neurodegenerative disease management in South Korea.As the population ages, the reliance on these diagnostic methods will likely increase, highlighting their importance in the evolving landscape of healthcare.

Neurodegenerative Disease Market Treatment Type Insights

The South Korea Neurodegenerative Disease Market is expanding significantly, with a marked focus on the Treatment Type segment that encompasses various approaches critical for managing these complex diseases. Medication is a prominent strategy, aiming to alleviate symptoms and slow disease progression, particularly in conditions like Alzheimer's and Parkinson's. Meanwhile, Therapy addresses cognitive and physical aspects affected by neurodegenerative disorders, offering essential rehabilitation and psychological support crucial for enhancing patients' quality of life.Rehabilitation plays an important role in helping individuals recover or maintain their functional abilities, emphasizing personalized procedures tailored to specific needs. Surgical Interventions are also noted for their potential in treating advanced stages of certain neurodegenerative diseases, providing an essential option when other treatments have ceased to be effective. The growth in the South Korea Neurodegenerative Disease Market revenue is driven by an aging population and increasing awareness regarding these conditions. Furthermore, the integration of advanced technologies into treatment methodologies presents opportunities for innovative therapeutic options, as healthcare professionals seek to improve patient outcomes through more effective management techniques.The trends observed in this sector reflect a commitment to enhancing the standard of care and addressing the challenges posed by neurodegenerative diseases within South Korea's healthcare system.

Neurodegenerative Disease Market Route of Administration Insights

The Route of Administration segment within the South Korea Neurodegenerative Disease Market showcases a diverse landscape that is crucial for effective treatment delivery. Oral administration remains popular due to its ease of use and patient compliance, making it a predominant choice among healthcare providers. Injectable routes are also significant, particularly for medications that require rapid absorption or specific dosage control, catering to patients who need precise treatment for neurodegenerative disorders. Intravenous methods are essential in acute care settings, allowing for immediate therapeutic effects, which can be life-saving in advanced cases.Meanwhile, Transdermal administration is gaining traction for its convenience and reduced gastrointestinal side effects, offering patients a non-invasive alternative for symptom management. With the South Korean population aging and the increasing prevalence of neurodegenerative diseases like Alzheimer’s and Parkinson’s, the variety of administration routes available plays a vital role in optimizing treatment efficacy and patient adherence. Furthermore, the ongoing innovation in drug delivery systems continues to enhance the performance of these administration routes, ultimately contributing to the overall development of the market.

South Korea Neurodegenerative Disease Market Key Players and Competitive Insights

The South Korea Neurodegenerative Disease Market is a dynamic and rapidly evolving sector that focuses on an array of conditions affecting the nervous system, such as Alzheimer's, Parkinson's disease, and multiple sclerosis. This market is driven by increasing prevalence rates of neurodegenerative diseases, elevating the demand for more innovative therapeutic solutions. Moreover, the strong research and development capabilities of local firms, along with a well-established healthcare infrastructure, have positioned South Korea as a competitive player in the Asia-Pacific neurodegenerative therapeutic landscape. The market is characterized by various strategic collaborations, partnerships between research institutions and pharmaceutical companies, as well as the growing trend of personalized medicine. These competitive insights indicate an industry ripe for both challenges and opportunities, with the potential for novel treatments to emerge amid rigorous regulatory frameworks and evolving patient needs.Celltrion has established itself as a prominent player in the South Korea Neurodegenerative Disease Market by leveraging its expertise in biotechnology and biosimilars. The company’s presence in this sector is built upon its strong commitment to research and development, resulting in the introduction of innovative therapeutic solutions aimed at alleviating symptoms associated with neurodegenerative conditions. The robust regulatory compliance and approval processes that Celltrion adheres to have bolstered its credibility in the market. Additionally, the company has developed strategic alliances within the healthcare ecosystem, further enhancing its competitive edge. These strengths enable Celltrion to effectively address both local and global market demands while maintaining a significant focus on advancing treatment options for patients suffering from neurodegenerative diseases in South Korea.LG Chem holds a noteworthy position in the South Korea Neurodegenerative Disease Market, distinguished by its comprehensive portfolio of products focusing on innovation and therapeutic efficacy. The company has made significant strides in research and development, culminating in key products aimed specifically at neurodegenerative diseases. LG Chem benefits from a strong market presence, underpinned by its extensive distribution network and collaborations with leading research institutions and healthcare providers in South Korea. The company has also engaged in strategic mergers and acquisitions, which have expanded its capabilities and strengthened its position within the neurodegenerative sector. By emphasizing high-quality solutions and being committed to continuous advancement in treatment methodologies, LG Chem remains a formidable competitor in addressing the growing challenges posed by neurodegenerative diseases in the region.

Key Companies in the South Korea Neurodegenerative Disease Market Include

• Celltrion
• LG Chem
• Hanmi Pharmaceutical
• Daewoong Pharmaceutical
• Green Cross
• Korea United Pharm
• Samsung Biologics
• Korea Research Institute of Bioscience and Biotechnology
• Novartis
• Biogen
• Roche
• Medytox
• Korea Institute of Science and Technology
• Pharmaron Beijing
• SK Biopharmaceuticals

South Korea Neurodegenerative Disease Market Industry Developments

The South Korea Neurodegenerative Disease Market has witnessed significant developments recently. In October 2023, LG Chem announced progress in its Research and Development pipeline for neurodegenerative treatments, focusing on Alzheimer’s disease therapies. Meanwhile, SK Biopharmaceuticals has been recognized for its breakthrough drug for epilepsy, reflecting the growing momentum in the biopharmaceutical sector related to neurodegenerative disorders. Hanmi Pharmaceutical and Daewoong Pharmaceutical are also actively collaborating to explore innovative treatments aimed at neurodegeneration, showcasing a trend towards joint ventures in product development. In terms of market valuation, major players like Samsung Biologics reported increased revenue due to heightened demand for biologics, particularly in treatments for neurodegenerative diseases. The market's growth has also been bolstered by funding from the Korean government, which is directing resources into biotechnology startups focused on neurodegenerative research. In terms of mergers and acquisitions, there have been speculations surrounding Green Cross and future collaborative efforts in developing neurodegenerative disease therapies, though no formal announcements have been made as of now. The South Korean neurodegenerative disease market continues to evolve, driven by innovation and strategic partnerships.

South Korea Neurodegenerative Disease Market Segmentation Insights

Neurodegenerative Disease Market Disease Type Outlook

• Alzheimer's Disease
• Parkinson's Disease
• Multiple Sclerosis
• Amyotrophic Lateral Sclerosis
• Huntington's Disease

Neurodegenerative Disease Market Diagnosis Method Outlook

• Neurological Examination
• Imaging Techniques
• Cerebrospinal Fluid Analysis
• Electrophysiological Tests

Neurodegenerative Disease Market Treatment Type Outlook

• Medication
• Therapy
• Rehabilitation
• Surgical Interventions

Neurodegenerative Disease Market Route of Administration Outlook

• Oral
• Injectable
• Intravenous
• Transdermal

Report Attribute/Metric Source:	Details
MARKET SIZE 2023	442.0(USD Million)
MARKET SIZE 2024	466.6(USD Million)
MARKET SIZE 2035	1200.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	8.967% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	Celltrion, LG Chem, Hanmi Pharmaceutical, Daewoong Pharmaceutical, Green Cross, Korea United Pharm, Samsung Biologics, Korea Research Institute of Bioscience and Biotechnology, Novartis, Biogen, Roche, Medytox, Korea Institute of Science and Technology, Pharmaron Beijing, SK Biopharmaceuticals
SEGMENTS COVERED	Disease Type, Diagnosis Method, Treatment Type, Route of Administration
KEY MARKET OPPORTUNITIES	Increasing aged population, Growing prevalence of Alzheimer's, Advancements in genetic therapies, Rising demand for personalized medicine, Enhanced diagnostic technologies.
KEY MARKET DYNAMICS	Aging population, Increasing healthcare expenditure, Rising prevalence of diseases, Advancements in treatment options, Growing research funding
COUNTRIES COVERED	South Korea